• Skip to primary navigation
  • Skip to main content

National Forum

  • Home
  • About
    • Advisory Leadership Council
    • Board of Directors
    • 2021-22 Strategic Plan
    • History
    • National Forum Awards
    • Team
    • Support
  • Collaborations
    • Counter Cholesterol™
    • Flu Prevention
    • Know Your Numbers
    • Million Hearts®
      • Million Hearts® Stakeholders Flu Vaccination Campaign ’22
    • Move with the Mayor™
    • Signature Reports
    • Stronger Hearts™
    • Value & Access
      • Value & Innovation Forum
  • Events
    • National Forum and Member Events
    • Health Equity Benefits Everyone – January 2023
    • 2022 Annual Meeting
    • 2022 Mid-Year Virtual Convening
    • 2021 Annual Meeting
    • 2021 Mid-Year Virtual Convening
    • Heart Failure Roundtable
    • Value & Innovation Forum
    • Meeting Archives
      • 2020 Annual Meeting
      • 2020 Mid-Year Meeting
      • 2019 Annual Meeting
      • 2019 Virtual Convening on Stroke
      • 2019 Mid-Year Member Meeting
      • 2018 Annual Meeting
      • 2018 Mid Year Meeting
  • Members
    • Membership
  • Newsroom
  • Search Toggle
  • Skip to content
Loading Events

« All Events

  • This event has passed.

ASPC Breakfast Symposium: Town Hall Series on Improving Access to PCKS9 Inhibitors Issues & Recommendations

Monday, November 13, 2017 @ 6:30 am - 8:30 am

  • « National Alliance of Healthcare Purchaser Coalitions Annual Conference
  • Overview of the new Best Practices Guide for Cardiovascular Disease Prevention Programs »
In 2016, the American Society for Preventive Cardiology (ASPC) sought to address patient barrier to access PCSK9 inhibitors by bringing together various stakeholder organizations for two Town Hall events entitled “Unraveling a Therapeutic Conundrum: Barriers to Access PCSK9 Inhibitors.” The ASPC and other stakeholder groups – National Lipid Association, American Association of Clinical Endocrinologists, American College of Cardiology, and FH Foundation — identified access issues and recommended pragmatic solutions. From the 2016 series, the ASPC and stakeholders produced a publication to summarize the identified access issues and recommended solutions entitled “PCSK9 Inhibitor Access Barriers: Issues and Recommendations: Improving the Access Process for Patients, Clinicians, and Payers.”
Join us as we discuss this publication that summarizes barriers to access PCSK9 inhibitors, and learn about new tools and resources to overcome this hurdle in accessibility. Read our paper on the latest findings and solutions to accessing PCSK9 inhibitors by clicking here. This non-CME breakfast symposium.
This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.
This activity is sponsored by Amgen, Sanofi and Regeneron.
  • Google Calendar
  • iCalendar
  • Outlook 365
  • Outlook Live

Details

Date:
Monday, November 13, 2017
Time:
6:30 am - 8:30 am
Event Categories:
Partner face-to-face event, Value & Access
Website:
https://www.aspconline.org/barriers/PCSK9

Organizer

Vivian Grifantini
Phone:
(904) 309-6212
Email:
vgrifantini@aspconline.org

Venue

Anaheim Marriott
700 West Convention Way, Grand Ballroom F
Anaheim, CA
+ Google Map
View Venue Website
  • « National Alliance of Healthcare Purchaser Coalitions Annual Conference
  • Overview of the new Best Practices Guide for Cardiovascular Disease Prevention Programs »

1150 Connecticut Ave., NW, Suite 300, Washington, DC 20036 Phone: (866) 894-3500
Copyright © 2023 National Forum for Heart Disease & Stroke Prevention. All Rights Reserved
  • Facebook
  • Twitter
  • YouTube
Contact

"*" indicates required fields

Name * Required
This field is for validation purposes and should be left unchanged.